• AusCann and Canopy are working to become the leading suppliers of medical cannabis products to the Australian market
• AusCann and Canopy are proposing to enter into a supply arrangement, which will see AusCann distributing products through an expanded network and developing an expanded pipeline covering multiple disease areas
• AusCann to scale up its existing medical liaison team and building an independent clinic network of allied partners to educate doctors about the products
Tuesday, 24 April 2018 – Leading medical cannabis company AusCann Group Holdings Limited (ASX:AC8) (‘AusCann’ or ‘the Company’) is pleased to announce that it has received an import permit under its existing import licence and will soon receive finished cannabis oils from its major shareholder, Canopy Growth Corporation (Canopy Growth).
AusCann and Canopy Growth are pursuing opportunities in several key areas in Australia including the importation, distribution, and local production of medical cannabis products.
For further information please download PDF attached:
Download this document